The trial is reported to be conducted at approximately 180 sites in the United States and other countries, in addition to Brazil and Mexico.
“Our Phase 3 program is intended to be as physically powerful as possible, can have up to 60,000 participants and will take place in locations with the highest occurrence rates,” Johnson’s spokesman said.
“We can verify that plans and recruitment are underway for our Phase 3 program, which is a matter of interim knowledge of Phase 1/2a trials and regulatory approval,” he added.
The drug manufacturer is using epidological knowledge where studies deserve to take a position and will soon make a final decision, according to the company.
Brazilian fitness regulator Anvisa announced Tuesday that it approved Tier III clinical trials for a COVID-19 vaccine developed through Johnson’s pharmaceutical subsidiary.
Another vaccine manufacturer, Moderna Inc and Pfizer, aims to recruit up to 30,000 volunteers for their complex studies.
Britain said it would buy COVID-19 vaccines from Johnson
(With input)
Click here to read the Mint ePaperLivemint.com is now on Telegram.Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.